Genmab — Oktober 2017
-
Morphosys stiger over 6% i dag og er i det hele taget steget meget i år. Gad vide om dagens stigning har en sammenhæng til retssagen?
-
Selvfølgelig ... det så jeg da godt tilbage i tråden.
-
Retssagen er berammet til 11. februar 2010 og citi skrev: The claim construction rulings were made available from the District Court of Delaware (opinion available-on-request). The headlines are unhelpful for JNJ/Genmab, where the court adopted MorphoSys’s version of the three disputed terms cited in patents ‘746 and ‘061
-
As previously reported, net sales were USD 87 million in the rest of the world. This figure was negatively impacted by a one-time adjustment of approximately USD 20 million related to accruals for retroactive reimbursement matters in Germany and France.
-
Det var de godt nok længe om, men bedre sent end aldrig
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind